Kornimate/medical-research-clean huggingface dataset:
urinary circulating tumor dna detection in non-small cell lung cancer: a prospective study

Conditions: Carcinoma; Non-small-cell Lung Cancer; Lung Neoplasms

Summary: this study will evaluate the feasibility and effectiveness of urinary ctdna detection and dynamic monitoring during treatment of nsclc patients prospectively,by collecting and detecting tumor tissues, peripheral blood samples and urine samples of nsclc patients.

liquid biopsy, specifically through the assessment of circulating tumor dna(ctdna) from peripheral blood, has shown great promise in lung cancer diagnosis and therapeutic monitoring. urinary samples are completely non-invasive and easily obtainable compared to blood and tissue extraction. to date, only a limited number of published studies have examined the feasibility of ctdna detection from urine. this study will collect tumor tissues, pretreatment peripheral blood samples and urine samples from different tnm stages of nsclc patients, and detect egfr gene mutations in paired samples.

Eligibility criteria:
inclusion criteria: * aged 18 to 80 years * histologically confirmed diagnosis of stage non-small cell lung cancer undergoing surgical resection * completed and explicit information about tnm staging * paired specimens including tumor tissues, and both peripheral blood samples and urinary samples before and after surgery. * patients must have given written informed consent exclusion criteria: * unable to comply with the study procedure * malignant tumor history within the past 5 years * coexisting small cell lung cancer * unqualified tissue, blood or urine samples

Keywords: non-small-cell lung cancer circulating tumor dna urine
comparison of melphalan-prednisone (mp) to mp plus thalidomide in the treatment of newly diagnosed very elderly patients (> 75 years) with multiple myeloma

Conditions: Newly Diagnosed, Multiple Myeloma

Summary: in multiple myeloma, combination chemotherapy with melphalan plus prednisone has been usedsince the 1960s and is regarded as the standard of care in very elderly patients. we assess whether the addition of thalidomide at 100 mg/day to this combination would improve survival.


Eligibility criteria:
inclusion criteria: * stage ii or iii multiple myeloma according to durie and salmon criteria, patients older than 75 years, previously untreated patients. exclusion criteria: * prior history of another neoplasm (except basocellular cutaneous or cervical epithelioma) * primary or associated amyloïdosis * world health organisation performance index of at least 3 * significant renal insufficiency with creatinine serum levels of 5.0 mg per deciliter or more * cardiac or hepatic dysfunction * cerebral circulatory insufficiency * absolute contraindication to corticosteroids * peripheral neuropathy clinically significant * history of venous thrombosis during the last 6 months * hiv or hepatitis b or c positivity * patients who had geography, social, or psychological conditions which might prevent adequate follow-up.

Keywords: multiple myeloma, very elderly patients, thalidomide
intra-articular pulsed radiofrequency with steroids injection versus intra-articular steroids injection in chronic sacroiliac joint arthritis

Conditions: Pain Management

Summary: the sacroiliac joint is located between the pelvis and base of the spine, the sacroiliac joints are strong, stable joints that allow for little movement. while these joints do not bend like a knuckle or knee, they are susceptible to degenerative arthritis. sacroiliac joint pain is one of the most common causes of chronic low back pain, accounting for 10% to 27% of patients with chronic lower back pain. it is known to be caused by abnormal motion in this joint, namely, too much motion or too little motion. patients with pain experience various degrees of pain in the low back, groin, buttock, or posterior thigh.

the pain starts when the sacroiliac joint gets inflamed. there are several reasons it could happen. it could be hurt when playing sports or if fall down. sometimes start hurting when the ligaments that hold the si joint together are damaged, which may make the joint move abnormally. the pain associated with sacroiliitis most commonly occurs in the buttocks and lower back. it can also affect the legs, groin and even the feet.

Eligibility criteria:
inclusion criteria: * all patients must have chronic pain more than 6 months and have failed medical treatment. exclusion criteria: * infection at the site of injection * opioids addiction * coagulopathy or another bleeding diathesis * those who refuse to participate in the study * ankylosing spondylitis patients

Keywords: chronic sacroilitis,radiofrequancy,intraarticular steroids injection
study of lymphatic drainage mapping in oropharyngeal cancers

Conditions: Oropharynx Cancer

Summary: the purpose of the study is to see how practical it is to inject a radiotracer called 99m-technetium sulfur colloid around the tumors for the imaging of patients with oropharyngeal cancer.

this study will evaluate a technique called lymphatic drainage mapping. this is a technique where a radiotracer (a radioactive material that can be seen with a special computed tomography \[ct\] scanner to create 3d images) is injected into a vein around the tumour, either with local anesthesia or under general anesthesia. the radiotracer that will be used for the lymphatic drainage mapping is called 99m-technetium sulfur colloid. images will be taken of neck to detect the movement of the radiotracer. this will allow the doctors to see the drainage pattern of the lymph nodes in the neck. the information from this study will be used to better understand the tendency for oropharyngeal cancers to spread to lymph nodes. in addition, the information from this clinical trial will be used in future clinical studies to help specialists identify strategies to help plan treatment based on this type of imaging study.

Eligibility criteria:
inclusion criteria: * patient has lateralized oropharyngeal carcinoma (tonsil or tongue base) not involving midline * has squamous cell carcinoma, t1-3 tumours, with no contralateral nodes on clinical exam or axial imaging * human papillomavirus (hpv) positive or negative * patient should have normal organ function as per investigator judgement * patient is planned for definitive or adjuvant radiotherapy (rt) or chemo radiotherapy (crt) with bilateral neck rt, or surgery * eastern cooperative oncology group (ecog) performance status 0-1 exclusion criteria: * t4 tumours * contralateral/bilateral nodal disease or node(s) \> 6cm on clinical exam or axial imaging or positron emission tomography (pet) * primary tumour involving or crossing midline * soft palate or posterior pharyngeal wall tumour subsites * previous head and neck cancer * previous radiotherapy (rt) to the head and neck * previous neck dissection * distant metastases * prior invasive malignancy (except non-melanoma skin cancer) unless disease free for 3 years * prior radiotracer allergy * multiple primary head and neck cancers * pregnancy

Keywords: lymphatic drainage mapping 99m-technetium sulfur colloid
copla study: treatment of severe forms of coronavirus infection with convalescent plasma

Conditions: COVID-19

Summary: covid-19 disease has become a very serious global health problem. treatments for severe forms are urgently needed to lower mortality. any procedure that improves these forms should be considered, especially those devoid of serious side effects.there is not enough published information on the use of allogeneic convalescent plasma (acp) in the treatment of severe forms of covid-19. the use of acp can be combined with other treatments and has very few adverse effects. it takes 10-14 days for sars-cov2-infected patients to produce virus-neutralizing antibodies: within that time they can develop serious complications and die. injecting pac into patients with severe forms of covid-19 shortens the period of risk while the patient produces the antibodies.


Eligibility criteria:
inclusion criteria: * patients with sars-cov2 infection who have had a serious evolution and are in an icu * with or without ventilatory assistance * treated or not with hydroxychloroquine 200 mg. every 12 hours * indistinct sex * older than 18 years * signed informed consent exclusion criteria: * patients treated with the following medications: azithromycin, ritonavir / lopinavir, remdesivir, interferons, ruxolinitib, tocilizumab. * patients with severe kidney failure who require replacement therapy.
evaluating the role of thrombin in saphenous vein graft failure after heart bypass surgery

Conditions: Coronary Artery Bypass; Thrombosis

Summary: heart bypass surgery, also known as coronary artery bypass graft (cabg) surgery, creates a detour around the blocked part of a heart artery to restore blood supply to the heart muscle. the saphenous vein, located along the inside of the leg, is commonly used to create the bypass in a cabg surgery. an abnormal increase in the blood clotting protein thrombin may cause the saphenous vein graft to close up and eventually fail. this study will evaluate the relationship between thrombin levels and saphenous vein graft failures in people undergoing a cabg procedure.

the saphenous vein, which runs from the ankle to the groin along the inside of the leg, is commonly used as a graft for people undergoing a cabg surgery. the vein is removed from the leg and reattached to the heart to create a detour around the blocked part of a coronary artery. following this procedure, many people are prescribed aspirin as a way to increase the chance that the graft procedure will be successful. however, saphenous vein graft failure may still occur in some people, indicating a need to understand why this happens and who might be at risk for graft failure. thrombin, a protein involved in the blood clotting process, is somehow related to aspirin resistance, abnormalities in blood flow, and cell disruption within the saphenous vein, all factors thought to increase the risk of graft failure. the purpose of this study is to evaluate the likelihood that a burst in thrombin contributes to graft failure in people who have recently undergone a cabg procedure using the saphenous vein. this study will enroll individuals undergoing cabg surgery at the university of maryland. prior to and immediately following surgery, an incision will be made in the skin and the time required for the blood to form a clot will be determined. during surgery, participants' blood vessels will be examined using imaging and cell analysis techniques. blood collection will occur before surgery, immediately after surgery, and on days 1, 3, and 30 following surgery. a portion of blood will be frozen for future analysis. an x-ray of the saphenous vein will be performed on day 5 and again at a follow-up visit 6 to 12 months following surgery. kidney function will be measured at both of these visits prior to the x-ray procedure. at the second visit, health and mental status questionnaires will be completed.

Eligibility criteria:
inclusion criteria: * scheduled for cabg surgery at university of arizona university medical center (umc) * for females, willing to use a reliable form of birth control for the duration of the study exclusion criteria: * non-dermatologic allergy to intravenous (iv) radiographic contrast * creatinine levels greater than 2.0 mg/dl * pregnant

Keywords: virchow's triad thrombin graft failure
clinical applications of round window imaging anatomy in cochlear implant surgery

Conditions: Sensorineural Hearing Loss (Disorder)

Summary: the purpose of this study is to measure the size of the round window niche and its relation to the mastoid segment of the facial nerve and the mastoid cortex, using high resolution computerized tomography of the temporal bone, in order to assess preoperatively what is the extent of obstruction of the round window membrane and whether there is a surgical possibility of round window approach in the insertion of electrode array into the cochlea

the assessment of the anatomy of the round window will be executed using the stractured measuring software used for imaging of the bnai zion medical center (carestream pacs ver. 11.0, carstream health inc.) in iac window (centered at 700 with a total width of 4000) in the available zoom by the software (usually 400-800%). measuring the length (mm) and angle will be executed by the software's structured rulers. measuring protocol: 1. measured scans: one taken in an orbito-meatal plane 2. chosen slices: where both the round window niche and the external ear canal are seen on the same slice 3. distances measured: 1. distance 1: between the anterior edge of the round window niche and the cortex of the mastoid, with a minimal distance of 0.5mm to the posterior wall of the external ear canal 2. distance 2: between the posterior edge of the round window niche and the cortex of the mastoid, with a minimal distance of 0.3mm to the anterior edge of the mastoid segment of the facial nerve. 3. distance 3: the size of the round window niche (from its anterior to posterior edges) 4. distance 4: between the anterior (most medial) edge of the round window membrane to a point at least 0.3mm anterior to the mastoid segment of the facial nerve. 5. distance 5: between the posterior (most lateral) edge of the round window membrane to a point at least 0.3mm anterior to the mastoid segment of the facial nerve 6. distance 6: size of round window membrane (anterior/medial to posterior/lateral) 7. distance 7: between the lateral edges of distance 1 and 2 marking the cortical size of the "working channel" created between the lines (from the cortex to the round window). 4. angles measured: 1. between distance 1 and 7 - marking the angle of the "working channel" relatively to the cortex 2. between distance 1, passing in the middle of distance 3 to the middle of distance 6 - marking the angle of possible insertion from the working channel into the cochlea

Eligibility criteria:
inclusion criteria: * age 20 years old or older * high resolution computerized tomography of the temporal bone (slices ≤1mm) before the surgery * on the measured slices both the round window niche and the posterior wall of the external ear canal are seen exclusion criteria: * inner, middle or external ear malformation * temporal bone malformation * status post cochlear implant * status post temporal bone trauma * slices were the round window niche and the posterior wall of the external ear canal are not seen on the same slice
effectiveness of individualized homeopathic treatment in perennial allergic rhinitis

Conditions: Rhinitis

Summary: a total of 41 adults with perennial allergic rhinitis were enrolled in a first double-blind placebo-controlled phase for six months, and treated on a weekly basis with sublingual doses of single individualized homeopathic medicines or placebo. after this closed initial phase, all patients were invited to participate in an long-term open-label controlled phase, in that they would receive homeopathic treatment for the maximum period of 36 months, and the results were compared with the improvement of initial phase. signs and symptoms scores, rescue medication requirements and quality of life were assessed by questionnaires and personal clinical evaluation by a same independent researcher, before and after each phase. primary and secondary clinical outcome were, respectively, specific and general allergic signs and symptoms scores. total ige titles were performed before and after each phase.


Eligibility criteria:
inclusion criteria: * moderate rhinitis * to assign written informed consent exclusion criteria: * other chronic diseases * corticosteroid use * pregnancy

Keywords: allergy rhinitis homeopathy double-blind
study of investigational regimen combining fda approved hiv drugs in hiv subjects experiencing early virologic failure

Conditions: HIV Infection

Summary: this study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining fda approved hiv drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen.


Eligibility criteria:
inclusion criteria: * currently on an initial haart (highly active antiretroviral therapy) regimen of 3tc/zdv or 3tc/d4t and a pi (protease inhibitor) -boosted or unboosted- or nnrti (non-nucleoside reverse transcriptase inhibitor). * plasma hiv - 1 rna was \<400 copies/ml on at least 2 documented occasions prior to viral rebound. * have a plasma hiv - 1 rna value \>400 copies/ml and \<10,000 copies/ml on 2 documented successive occasions (including screen) separated by at least 2 weeks. * a cd4+ lymphocyte count less than or equal to 100. exclusion criteria: * have not taken abacavir (ziagen or trizivir) or tenofovir (viread) previously. * have not had an aids defining illness within 30 days of screen. * pregnant or breast-feeding. * specified viral genotypes upon screening. * and other inclusion or exclusion criteria to be evaluated by the physician.

Keywords: hiv-1 trizivir tenofovir
thymalfasin and recombinant human il-2 injections in treating lymphocytopenia for patients with malignant hematological tumors

Conditions: Hematological Malignancy; Lymphocytopenia

Summary: to evaluate the efficacy and safety of thymalfasin for injection in combination with recombinant human interleukin-2 injections in the treatment of lymphocytopenia in patients with malignant hematological tumors

a prospective, randomized controlled study is proposed to evaluate the efficacy and safety of thymalfasin for injection in combination with recombinant human interleukin-2 injections, recombinant human interleukin-2 injections as a monotherapy, and a non-intervention group. follow-up observations will also be conducted.

Eligibility criteria:
inclusion criteria: 1. patients with histologically confirmed myeloid, b lymphocyte, and plasma cell-derived malignant hematological tumors. 2. lymphocyte count ≤ 0.8×109/l or cd4+t cell count ≤ 0.35×109/l. 3. age ≥ 18 years, both male and female, with an expected survival period of more than 3 months. 4. estimated creatinine clearance rate ≥ 30 ml/min. 5. ast and alt ≤ 3.0 x uln. bilirubin ≤ 1.5 x uln. 6. ecog ≤ 2. 7. able to understand and voluntarily provide informed consent. exclusion criteria: 1. active autoimmune disease. 2. patients considered to have a malignant t-cell clone. 3. within 8 days after chemotherapy for lymphoma and within 14 days after chemotherapy for aml. 4. tumor involvement in the bone marrow leading to hematopoietic suppression (neutrophils \<1.0×10\^9/l, hb\<70g/l, plt\<50×10\^9/l). 5. hiv-positive patients and/or active hbv or hcv infection (as evidenced by positive hbv-dna and hcv-rna test records). 6. patients with chronic respiratory diseases requiring continuous oxygen, or with significant past medical history of kidney, neurological, psychiatric, endocrine, metabolic, immune, hepatic, cardiovascular diseases. 7. immunosuppressive treatment (such as cyclosporine, corticosteroids, ruxolitinib, jak1/2 inhibitors, etc.) within the past 5 days. 8. psychiatric disorders that would interfere with study participation. 9. patients who have undergone allogeneic hematopoietic stem cell transplantation. 10. consideration of allergy to thymalfasin or interleukin-2. 11. any other condition that the researcher believes makes the patient unsuitable for this trial.
normal values of facial thermography

Conditions: Healthy; Allergy; Allergic Rhinoconjunctivitis

Summary: an objective of this study is to standardize temperature values derived from thermograms of the facial region. it is anticipated that the mean temperature of a defined region of interest, such as the eyes, nose, or sinuses, might be useful for future applications. the investigators will attempt to determine normal temperature ranges based on participants' age and gender.

medical thermography is a noninvasive technique that allows an examiner to visualize and estimate the temperature of the skin surface. an infrared scanning device is used to convert infrared radiation emitted from the skin surface into electrical impulses that can be captured as an image called a thermogram. during the past 20 years medical thermography has been used to study the pathology in the vascular, muscular, neural and skeletal systems. an objective of this study is to standardize temperature values derived from thermograms of the facial region. it is anticipated that the mean temperature of a defined region of interest, such as the eyes, nose, or sinuses, might be useful for future applications. this protocol addresses the definition of overall health, symptomology, and anthropometrical features (age, weight, height, body mass index and gender), and what effect, if any, each has on mean temperature. environmental conditions, mapping procedures, and image evaluations will also be standardized. we will attempt to determine normal temperature ranges based on participants' age and gender. future use of standardized values will be to assess the severity of rhinoconjunctivitis symptoms being experienced by a subject. subjects will make one visit to our clinic. they will be asked to acclimate to room temperature for at least 30 minutes. subjects are requested not to consume hot drinks or food for at least an hour before imaging and not to use any skin preparations such as creams or talcum powder. a picture of the participant's face will be taken using the thermal camera which will demonstrate the temperature of each facial area of interest. please note that participants in this study will take part on a completely voluntary basis. no payment will be provided.

Eligibility criteria:
inclusion criteria: * between ages 7 and 70 * no mobility problems * no restrictions in performing normal activities * no regular pain or discomfort * no anxiety or depression exclusion criteria: * restrictions in performing normal activities * regular pain * anxiety or depression * mobility problems

Keywords: healthy allergy allergic rhinoconjunctivitis